PDE4A and Alzheimer disease: Studies in APP/PS1 transgenic mice—a model for AD—have demonstrated that PDE4 inhibitors improve cognitive function, reduce depressive behaviors, and decrease neuronal apoptosis by increasing the Bcl-2/Bax ratio [9,39].